T
Totus Medicines
Designing life-changing medicines at genomic scale
About Totus Medicines
Totus Medicines is a pioneering biotech startup that leverages its proprietary platform to discover and develop drugs at an unprecedented scale, speed, and efficiency. The company operates in the pharmaceutical and biotechnology market, focusing on creating a comprehensive catalog of drugs targeting the entire human genome. This innovative approach allows Totus Medicines to design life-changing medicines, particularly for diseases that have been historically difficult to treat.
The core technology of Totus Medicines revolves around Power Covalent molecules. These molecules act as a universal key to unlock previously undruggable targets, which are proteins or genes that traditional drugs cannot effectively target. This method has been instrumental in developing some of the most effective therapeutics in history, such as penicillin and certain oncology drugs.
Totus Medicines primarily serves clients in the healthcare sector, including hospitals, clinics, and research institutions. Their breakthrough cancer drug, TOS 358, targets the PI 3 oncogene, which is highly mutated in various cancers like breast, colorectal, lung, and bladder cancer. This drug has shown promising results in inducing stasis and regression in PI 3 mutant models, addressing a significant unmet need in oncology.
The business model of Totus Medicines is based on drug discovery and development. They generate revenue through the commercialization of their proprietary drugs, partnerships with pharmaceutical companies, and potential licensing deals. By focusing on high-impact diseases such as cancer and heart disease, Totus Medicines aims to bring transformative treatments to market, thereby improving patient outcomes and generating substantial financial returns.
The leadership team, headed by Tom Hughes, PhD, brings extensive industry experience in drug discovery and development. Hughes has a proven track record, having held significant positions at Navitor Pharmaceuticals, Zafgen Inc., and Novartis.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 36
- Open positions
- None listed
- Dealroom signal
- 74.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Drug Development, Biotech and Pharma, Techbio, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2023 | $66M | $264M | DCVC | ↗ |
| SERIES AOther financing | Dec 2021 | $40M | $160M | DCVC · Northpond Ventures | ↗ |
Growth signals
Latest recorded traffic for Totus Medicines is 2.3K monthly website visits, up 27.8% over the last three months. Totus Medicines's team declined 5.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Totus Medicines in its local ecosystem
The Totus Medicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Social Impact Capital
DCVC
Northpond Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Totus Medicines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Totus Medicines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









